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ABSTRACT: We optimized the assays used to measure inhibition of rat and human α-glucosidases (sucrase and maltase
activities), intestinal enzymes which catalyze the ﬁnal steps of carbohydrate digestion. Cell-free extracts from fully diﬀerentiated
intestinal Caco-2/TC7 monolayers were shown to be a suitable source of sucrase−isomaltase, with the same sequence as human
small intestine, and were compared to a rat intestinal extract. The kinetic conditions of the assay were optimized, including
comparison of enzymatic and chromatographic methods to detect the monosaccharide products. Human sucrase activity was
more susceptible than the rat enzyme to inhibition by acarbose (IC50 (concentration required for 50% inhibition) = 2.5 ± 0.5 and
12.3 ± 0.6 μM, respectively), by a polyphenol-rich green tea extract, and by pure (−)-epigallocatechin gallate (EGCG) (IC50 =
657 ± 150 and 950 ± 86 μM respectively). In contrast, the reverse was observed when assessing maltase activity (e.g., EGCG:
IC50 = 677 ± 241 and 14.0 ± 2.0 μM for human and rat maltase, respectively). 5-Caﬀeoylquinic acid did not signiﬁcantly inhibit
maltase and was only a very weak inhibitor of sucrase. The data show that for sucrase and maltase activities, inhibition patterns of
rat and human enzymes are generally qualitatively similar but can be quantitatively diﬀerent.
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1. INTRODUCTION
The prevalence of type 2 diabetes has doubled over the last 30
years and aﬀects an estimated 1 in 10 worldwide.1 A meta-
analysis of intervention studies suggests that reducing the
glycaemic impact of the diet can reduce the risk of developing
type 2 diabetes.2 One current management strategy for diabetes
is based on reducing the glycemic impact though inhibition of
α-glucosidase enzymes in the gut, and this can be achieved by
regular consumption of the antihyperglycemic drugs acarbose,
voglibose, and miglitol.3 In an intervention study where
acarbose was taken daily for 3 yr, the risk for developing type
2 diabetes was reduced by 6% compared to the control.4
However, these drugs exhibit some gastrointestinal side eﬀects,
and so natural products are sought as possible alternatives or
adjuncts.
Consumption of polyphenols has been associated with
decreased incidence of type 2 diabetes and cardiovascular
disease,5−7 in part owing to the potential for certain
polyphenols to inﬂuence sugar digestion and absorption in
the small intestine.8 Carbohydrate digestion can be attenuated
by inhibition of α-glucosidases such as sucrase and maltase and
of monosaccharide transport across enterocytes.6 Because
polyphenols have the potential to act in the same way as
acarbose, this could also provide a mechanism for reduction in
diabetes risk ascribed to polyphenol-rich diets.8 However, there
are a number of limitations in the assays for assessing α-
glucosidase activities which could lead to misleading results and
poor predictive capacity for subsequent in vivo testing in
volunteers. Although human enzymes are always the intended
target for therapeutic interventions, many studies have used the
more readily available rat intestinal preparations in vitro. This is
coupled with a variety of detection methods for the products,
typically enzyme-linked spectrophotometric assays based on
glucose oxidase or hexokinase,9−12 which are susceptible to
inhibition themselves by the tested compounds,13 confounding
estimation of inhibition of the target α-glucosidase. Even
though hexokinase was reported to be the method of choice,13
we report data here showing that polyphenols can substantially
inhibit this enzyme.
The only intestinal enzyme able to hydrolyze sucrose is the
enzyme sucrase. Sucrase isomaltase (SI) is a highly N- and O-
glycosylated brush border type-II membrane protein with
various α-glucosidase activities and is traﬃcked to the cell
surface through association with lipid rafts.14 SI consists of two
subunits, sucrase and isomaltase, which are cleaved by luminal
proteases but remain associated through noncovalent inter-
actions.15 The sucrase subunit has both maltase (α-1,4) and
sucrase (α-1,2) activities, while the isomaltase subunit has
maltase (α-1,4) and isomaltase (α-1,6) activities.16 SI is
therefore involved in the digestion of both sugars and starch.
Type 2 diabetic patients have increased levels of SI, which
potentially increases the rate of sugar digestion and uptake and
exacerbates the problem, making it an interesting target for
inhibition.17 Caco-2 cells express sucrase−isomaltose after
diﬀerentiation and could be a suitable source of the enzyme
for in vitro experiments. However, it is conceivable that the
enzyme contains mutations in the cell line compared to human
Received: August 7, 2017
Revised: September 14, 2017
Accepted: September 15, 2017
Published: September 15, 2017
Article
pubs.acs.org/JAFC
© 2017 American Chemical Society 8643 DOI: 10.1021/acs.jafc.7b03678
J. Agric. Food Chem. 2017, 65, 8643−8651
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
tissue which, if present, could invalidate the use of the cell line
as a source of genuine human enzyme.
Some studies have used Caco-2 cells as a source of enzyme,
where the inhibition of α-glucosidases by mulberry leaves was
tested,18 but the method did not take into account any
subsequent transport and metabolism of the product. Other
assays have been reported19,20 but not optimized. Given the
potential importance of the assay in evaluating naturally
occurring compounds for acarbose-like activity, the aim of
this work was to optimize the assay for inhibition of human
sucrase and maltase activities and evaluate diﬀerences in
inhibition between the human and rat enzymes.
2. MATERIALS AND METHODS
2.1. Chemicals. Acarbose, 5-caﬀeoylquinic acid, sodium potassium
monobasic, sodium potassium dibasic, glucose, sucrose, maltose,
hexokinase glucose assay reagent, Bradford reagent, intestinal acetone
powder extract from rat, protease inhibitors, epigallocatechin gallate,
trypsin EDTA solution, L-cysteine, papain from papaya latex,
Dulbeccos’s modiﬁed Eagle’s Medium, nonessential amino acids,
penicillin−streptomycin solution, phosphate buﬀered saline (PBS),
and fetal bovine serum were purchased from Sigma-Aldrich, Dorset,
UK. Glutamax was from Thermo Fisher Scientiﬁc, Waltham, MA,
United States. Oasis MAX cartridges were purchased from Waters
Corporation, Milford, MA, United States. Green tea water-soluble
extract was from Nestle,́ Choladi, India. The Caco2/TC7 cell line was
a kind gift by Prof. Monique Rousset, Centre de Recherche des
Cordeliers, Paris, France. The green tea extract was analyzed by
HPLC21 and contained 199.8 mg/g (−)-epigallocatechin gallate, 124.4
mg/g (−)-epigallocatechin, 34.4 mg/g (−)-epicatechin gallate, and
23.3 mg/g (−)-epicatechin (w/w).
2.2. Equipment Used for Measurement of Enzyme Activity.
Absorbance measurements were performed on a Pherastar FS plate
reader from BMG labtech, Ortenberg, Germany. High performance
anion exchange chromatography with pulsed amperometric detection
(HPAE-PAD) was performed on the ICS4000 system from Thermo
Fisher Scientiﬁc.
2.3. Gene Sequencing. The sequencing of SI from Caco-2/TC7
cells used the following materials: RNAqueous Total RNA Isolation kit
from Thermo Fisher Scientiﬁc, GoScript Reverse Transcription
System from Promega, Madison, WI, United States, Cloneamp HiFi
PCR premix and In-fusion cloning kit from Takara Bio Europe, Saint-
Germain-en-Laye, France, primers from Sigma-Aldrich, Dorset, UK,
and zymoclean gel extraction PCR recovery kit from Zymo Research,
California, United States. Human RNA as a reference sample for
sucrase sequencing was from DV Biologics, California, United States.
2.4. Growth Conditions for Caco-2 Cells as a Source of
Human Enzyme for in Vitro Assays. Caco-2/TC7 cells were
routinely cultured at a density of 1.2 × 106 cells per 75 cm2 culture
ﬂask in standard medium consisting of Dulbeccos’s modiﬁed Eagle’s
Medium supplemented with 20% (v/v) fetal bovine serum, 2% (v/v)
Glutamax, 2% (v/v) nonessential amino acids, and 1% penicillin−
streptomycin solution. Cells were maintained in an incubator at 37 °C
with 10% CO2. Medium was replaced every 2 d and, at this seeding
density, 80% conﬂuence was reached in 3 d, at which point the cells
were subcultured by detaching with 0.25% trypsin. Cells were allowed
to fully diﬀerentiate for 21 d, and a crude lysate was prepared. The
cells were washed 3 times with cold phosphate buﬀered saline and cells
were scraped with 1 mL of assay buﬀer (10 mM phosphate buﬀer, pH
7.0) containing protease inhibitors. The cell lysates were snap frozen
in a dry ice and ethanol bath and stored at −80 °C until required. On
the day of assay, cell lysates were thawed, vortexed, and then passed
10−15 times though a 21G needle syringe, and this preparation is
referred to as a cell-free extract because it contains no intact cells.
Papain-digested lysates were also prepared to evaluate diﬀerent lysate
preparation methods. Fully diﬀerentiated cells were washed with warm
PBS and then incubated at 37 °C for 15 min with 2 mL papain
solution containing 1 mg/mL papain and 0.5 mg/mL L-cysteine.22
After the incubation, cells were scraped and transferred into Eppendorf
tubes and centrifuged at 210g for 10 min at 4 °C. The supernatant was
used for the assay. The protein content of the lysate, either crude or
papain-digested, was determined by Bradford assay,23 and the lysate
was diluted in assay buﬀer as required.
2.5. Extraction of mRNA from Caco-2/TC7 Cells, Conversion
to cDNA, and Sequencing of cDNA for Sucrase Isomaltase.
Total RNA was extracted using the RNAqueous Total RNA Isolation
kit according to the manufacturer’s protocol, and then 250 ng of total
RNA was converted into cDNA by reverse transcription using the
reverse transcription kit according the manufacturer’s protocol. The
gene was reverse transcribed in two parts with two sucrase−isomaltase
speciﬁc reverse primers A and B and ampliﬁed using primer pairs
speciﬁc to each segment (see Table S1) using Cloneamp HiFi PCR
premix. Primers contained overlapping ends for future cloning into a
vector (underlined and in italics). The PCR products from segment A
(bases 1−1811) and segment B (1174−5784) were separated on an
agarose gel extracted using Zymoclean gel extraction PCR recovery kit
and then cloned together using the In-fusion cloning kit. This kit uses
a recombinase enzyme which fuses the overlapping homologous
sequences together and resulted in the full SI coding region, which was
sent for DNA Sanger sequencing by Beckman Coulter Genetics using
the primers as found in Table S2. The RNA from a human intestinal
biopsy from DV Biologics was sequenced as a reference using the same
procedure.
2.6. Sucrase and Maltase Assays Using a Caco-2 TC7 Cell-
Free Extract. Assay samples of 250 μL contained sucrose or maltose,
with Caco-2/TC7 cell lysate preparation as the enzyme source in 0.1
M phosphate buﬀer pH 7.0. A time course was evaluated from 0 to 30
min, and assays to determine the speciﬁc activity in the lysate were
performed with a range of enzyme concentrations (total protein from
40 to 320 μg). The speciﬁc activity was determined as the amount of
substrate consumed per minute per mg of total protein in the assay.
The kinetic parameters Km and Vmax were determined using initial rates
derived from the selected enzyme concentration and incubation times
with substrate concentrations ranging from 1 to 60 mM. One enzyme
unit (U) is equivalent to the amount of enzyme that catalyzes the
hydrolysis of 1 μmol of substrate per min. For inhibition assays,
inhibitor was added to the reaction mixture at the indicated
concentrations: acarbose from 1 to 50 μM, EGCG from 100 to
1500 μM, GT from 0.5 to 5 mg/mL, and 5-caﬀeoylquinic acid from
100 to 500 μM. For inhibitors dissolved in DMSO to ensure solubility
(EGCG and 5-caﬀeoylquinic acid), control samples were included to
ensure no interference, and a maximum of 2% of the total reaction
volume was DMSO. Assay samples were incubated in a water bath at
37 °C for 10 min, and the reaction was stopped by placing the samples
in a boiling water bath for 10 min. Samples were centrifuged at
17 000g for 10 min.
2.7. Glucose Detection Methods: Hexokinase and HPAE-
PAD. The glucose produced in the enzyme reaction was quantiﬁed
enzymatically using hexokinase according to the manufacturer’s
protocol or chromatographically with HPAE-PAD, which has been
reported previously to measure glucose.24,25 Using HPAE-PAD,
glucose was chromatographically separated from fructose and sucrose
and could be quantiﬁed between 1 and 50 μM. Before HPAE-PAD
analysis, protein in the samples was precipitated by the addition of
acetonitrile (1:1 v/v), and samples were vortexed and centrifuged at
17 000g for 10 min. The resulting supernatant was diluted with
deionized water to fall within the calibration range, ﬁltered through a
0.2 μM PTFE ﬁlter, and maintained at 4 °C in the autosampler.
Capillary separation of carbohydrates was done using the capillary
CarboPac PA20 column, 0.4 × 150 mm with CarboPac PA20 Guard,
0.4 × 35 mm with the column at 30 °C and compartment at 15 °C.
The detection was performed using a gold working electrode and
palladium reference electrode with a collection rate of 2.00 Hz using
the waveform “Gold, Carbo, Quad” waveform. The analysis method
starts at 25 mM NaOH eluent for 10 min followed by a wash at 100
mM for 15 min and then re-equilibration at 25 mM from 25 to 38 min.
The ﬂow rate was 0.008 mL/min with 0.04 μL injection volume and
20× capillary overﬁll. Inhibitors were evaluated for potential
Journal of Agricultural and Food Chemistry Article
DOI: 10.1021/acs.jafc.7b03678
J. Agric. Food Chem. 2017, 65, 8643−8651
8644
interference by preparing and analyzing assay samples without
substrate containing inhibitor at the highest concentration used.
2.8. Eﬀect of Polyphenols on Hexokinase-Linked Assay and
Removal by SPE. To evaluate which polyphenols or polyphenol-rich
extracts interfere with the hexokinase assay, samples (250 μL)
containing 5 mM glucose were prepared in assay buﬀer with and
without polyphenols or extracts at their highest tested concentration
(see Section 2.6 above). The assay was performed using hexokinase to
measure the amount of glucose, and the samples were compared to the
control. The independent sample t test was performed to determine if
the inhibitors had signiﬁcant eﬀect on the assay. Any inhibitors which
interfered signiﬁcantly were removed by SPE prior to analysis in all
subsequent assays as follows: Oasis MAX 3 cc cartridges were
preconditioned with 1 mL of deionized water and 1 mL of methanol
and then dried under vacuum for 5 min. The sample collection tube
was placed under the cartridge, and 200 μL of test samples and
controls were passed through and collected. A ﬁxed volume was then
used in the hexokinase assay as indicated above. Removal of any
interference by SPE was conﬁrmed by evaluating separate polyphenol
samples spiked with glucose.
2.9. Sucrase and Maltase Assay Using a Rat Intestinal
Acetone Protein Extract. The enzyme assay was also optimized for
incubation time, substrate concentration, and linear range using an
enzyme preparation from powdered acetone protein extract from rat
intestine.21 For maltase, 4 mg solid/mL was used with 3 mM maltose
and 20 min incubation time. For sucrase, 20 mg solid/mL was used
with 16 mM sucrose and 20 min incubation time.
3.0. Data and Statistical Analysis. The percent inhibition was
determined by the following formula where the control is without
inhibitor:
= − ×% ([glucose] [glucose] )
[glucose]
100control inhibitor
control
Statistics were performed by one-way analysis of variance using
SPSS Statistics version 24, and statistical signiﬁcance was determined
by Tukey−Kramer multiple comparison test (p ≤ 0.05). The data are
presented as mean ± SEM with minimum of n = 3. Cell lysates were
prepared from three biological passages of cells and used for IC50
determinations.
3. RESULTS
3.1. Sucrase Isomaltase from Caco-2/TC7 Cells and
Human Small Intestine Has the Same Sequence,
Showing That the Former Is a Suitable Source of
Enzyme for in Vitro Assays. One of the goals was to
optimize an assay for assessing inhibition using human
diﬀerentiated Caco-2/TC7 cell extracts as a source of the
sucrase−isomaltase. Only the sucrase sequence from Caco-2
cells, and not from Caco-2/TC7 cells, has been reported,26 and
because even point mutations may under some circumstances
lead to alteration of enzyme activity,14 it was important to
establish that the sucrase sequence of the Caco-2/TC7 line was
the same as the human small intestinal enzyme. Based on
sequencing of sucrase from the Caco-2/TC7 clone, we conﬁrm
that it has a sequence identical to that of the human intestine
(sequencing results from Caco-2/TC7 are shown in Supporting
Information, Section S3). The reported Caco-2 cell sucrase
sequence,26 the reference human biopsy control sample from
DV Biologics, and the BC132860.1 sequence from the National
Institutes of Health Mammalian Gene Collection (MGC)
Program27 all reported the same sequence as that in the Caco-
2/TC7 cells. However, it should be noted that there is one base
diﬀerent at position 4632 (G → A) compared to one of the
sequences in the NCBI database (NM_001041.3).
3.2. Optimization of Human Sucrase−Isomaltase
Assay: Determination of Kinetic Parameters, Substrate
Concentration Dependence, and Assay Time Course
Linearity. A cell-free extract from Caco-2/TC7 cells was
evaluated as a source of sucrase and maltase for use in assays. A
time course was determined using 10 mM sucrose and maltose,
and maltase exhibited a linear production of glucose up to 15
min (Figure 1A) with sucrase linear up to 40 min (Figure 1B).
On the basis of this, an assay time of 10 min was selected for
both activities. The speciﬁc activity of maltase was 725 ± 36
mU/mg (Figure 1C) and for sucrase was 130 ± 4 mU/mg
(Figure 1D) and was proportional to total protein up to 1.28
and 0.64 mg/mL, respectively. The amount of protein chosen
for future assays was selected to ensure a linear initial rate: 0.05
and 0.02 U per assay for maltase and sucrase, respectively.
Using the conditions established, the apparent Km was 9.5 mM
and Vmax = 0.053 μmol/min for sucrose, and apparent Km was
7.5 mM and Vmax = 0.379 μmol/min for maltose (Figures 1E
and F, respectively). The sucrase and maltase apparent Km
values measured here were within the reported range for
human sucrase19,20,28 and for human maltase.20 Optimizing the
assay is extremely important to correctly evaluate and identify
inhibitors. Using the optimized assay conditions, acarbose
inhibited maltase activity (Figure 2) with an IC50 value of 5.7 ±
1.4 μM. When more enzyme was used (0.2 U/assay), the
reaction rate became nonlinear, and the IC50 value for acarbose
was estimated at 22.1 ± 2.9 μM (Figure 2), which was 4-fold
higher. Varying the substrate concentration had a less dramatic
eﬀect on the measured IC50 value. For sucrase, the measured
IC50 value for acarbose was unchanged over a 100-fold variation
in substrate concentration (Figure 3A). For maltose, there was
Figure 1. Optimization of assay parameters using cell-free extracts
from human Caco2/TC7 cells. Human maltase activity time course
(A), dependence on added protein (C), and Lineweaver−Burk plot for
determination of Km and Vmax (E). Human sucrase activity time course
(B), dependence on added protein (D) and Lineweaver−Burk plot for
determination of Km and Vmax (F). Solid lines indicate the linear part of
the curve. Error bars where not visible are smaller than the data point.
Results are presented as mean ± SEM (n = 3).
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a small eﬀect on the measured IC50 value when the substrate
concentration was greater than 10× the Km (Figure 3B).
3.4. Eﬀect of Papain Treatment on Enzyme Activities.
Sucrase−isomaltase is attached via a protein tail to the small
intestine brush border membrane. To determine if there could
be an advantage in removing it from the cellular membrane, we
used papain to release the enzyme from the brush border.
Although papain treatment gave an increase the speciﬁc activity
of both sucrase and maltase (Figures 4A and B), the inhibition
observed was unchanged (Figures 4C and D). It was therefore
concluded that the papain step did not oﬀer a signiﬁcant
advantage to the overall method for determining inhibition.
3.5. Determination of Possible Interference in the
Hexokinase-Linked Estimation of Glucose. Hexokinase
and glucose oxidase are commonly used enzymes for assessing
glucose concentration and both are commercially available in
the form of kits. Glucose oxidase is highly susceptible to
inhibition by polyphenols and other compounds,13,29 and
although hexokinase is less susceptible, it is still reported to be
inhibited.13 All compounds tested here were evaluated here for
direct inhibition of hexokinase. Glucose standards at 1 mM
were prepared in presence and absence of each inhibitor, and
the concentration of glucose was determined using the
hexokinase assay. EGCG at 1000 μM led to an apparent 23%
increase in glucose concentration (p < 0.001, n = 3); green tea
at 2.5 mg/mL caused an apparent 13% decrease in glucose
concentration (p = 0.002, n = 3), and 5-caﬀeoylquinic acid at
500 μM caused an apparent decrease of 10% (p < 0.001, n = 3).
Acarbose at 100 μM had no signiﬁcant eﬀect on the assay
compared to the control (p = 1.0, n = 3). These results indicate
that EGCG, green tea, and 5-caﬀeoylquinic acid all inhibited
hexokinase activity, whereas acarbose did not. On the basis of
these results, EGCG, green tea, and 5-caﬀeoylquinic acid must
be removed before assessing glucose production by sucrase or
maltase activities. SPE removal was tested and proved to
successfully remove all of the polyphenols before analysis using
hexokinase and so was incorporated into the protocol.
3.6. Comparison of Methods for Detection of Sugars.
Because several of the test compounds were shown to interfere
with the hexokinase assay, chromatographic quantitation of
sugars using HPAE-PAD was evaluated as a potential
alternative for estimation of product compared to the
enzymatic detection. Glucose is readily quantiﬁed using this
method.24,25 Good separation was achieved between glucose,
fructose, and sucrose, and a standard curve for glucose was
linear between 1 and 50 μM (Figures 5A and B) with limit of
detection = 0.5 μM and of quantitation = 1.0 μM. Sucrose
hydrolysis led to formation of glucose and fructose (Figure
5C); inhibition by EGCG was readily observed as a reduction
in glucose and fructose peaks (Figure 5C), but when used as a
substrate, sucrose was not normally measured as the peak for
this sugar was saturated. For maltose as substrate, inhibition
was apparent as a reduction in the glucose peak (Figure 5D).
The inhibitors tested here were also run to determine if they
contained any sugars or generated any interfering peaks. Of the
tested samples, only green tea contained glucose (Figure 6); at
5 mg/mL, it contained 0.36 mM glucose, reduced after SPE to
0.14 mM owing to dilution. The amount of glucose quantiﬁed
in enzyme assays after hydrolysis typically ranged from 0.4 to 2
mM, and so the glucose present in green tea (≤0.14 mM)
would signiﬁcantly interfere. Green tea standards were prepared
Figure 2. The eﬀect of amount of enzyme in the assay for the
inhibition of maltase by acarbose. Results are presented as mean ±
SEM (n = 3).
Figure 3. Eﬀect of substrate concentration on apparent inhibition.
Substrate concentrations of 1, 10 (∼Km), and 100 mM were evaluated
for sucrose (A) and 1, 7 (∼Km), 10, and 100 mM for maltose (B) were
used in the assay for inhibition by acarbose at 2.5 μM. Results are
presented as mean ± SEM (n = 3).
Figure 4. Eﬀect of papain treatment on enzyme activity and inhibition.
Caco-2/TC7 crude lysate or the supernatant from papain-digested was
used as the enzyme source for sucrase (A) or maltase (B) assay with
10 mM substrate, 10 min incubation time, and increasing amounts of
total protein. Acarbose inhibition of sucrase (C) and maltase (D)
determined using both preparations with 10 mM substrate, 10 min
incubation time, and increasing concentrations of acarbose. Results are
presented as mean ± SD (n = 3).
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over a range of concentrations and used to correct for the sugar
content.
To compare the chromatographic method with the
hexokinase-linked assay, maltase assays with and without
EGCG were analyzed by both methods (Table1). Before
glucose analysis by hexokinase but not HPAE-PAD, EGCG was
removed by SPE. The hexokinase-linked method showed
∼twofold greater variation than the chromatographic method
based on glucose detection (Table 1). The absolute
concentrations of glucose determined enzymatically were 43.0
± 4.3% lower, but the loss was consistent and readily corrected
for using standard curves. Importantly, the IC50 values were not
diﬀerent when determined enzymatically and chromatograph-
ically (677 ± 241 and 633 ± 35 μM, respectively; 3
independent determinations, p = 0.77) (Figure 7).
3.7. Inhibition of Polyphenols and Extracts on Sucrase
and Maltase Activity Using Enzyme from Human and
Rat Sources. On the basis of the results from above, the assay
conditions for maltase and sucrase were selected and are shown
in a ﬂowchart (Figure 8). Using these conditions, the IC50
values for acarbose, green tea, and EGCG for both sucrase and
maltase inhibition using the rat and human enzyme sources
were determined (Figure 9). The greatest inhibition of human
maltase activity was by green tea, with IC50 of 0.5 mg/mL,
which contains the equivalent of ∼200 μM EGCG (most
abundant polyphenol). Alone, pure EGCG at 677 μM was
Figure 5. Chromatographic estimation of sugars. Calibration curve for the quantiﬁcation of glucose standards by HPAE-PAD (A) as mean ± SEM
(linear ﬁt y = 0.274x; r2 = 0.99; average relative standard deviation 3.4%, n = 4, injection volume 0.04 μL) and representative chromatograms for
standards containing a mixture of glucose, fructose, and sucrose (B) where G = glucose, F = fructose and S = sucrose. Example chromatograms
showing sugar analysis from sucrase (C) or maltase (D) assays with and without EGCG at 500 μM.
Figure 6. Evaluation of interference in chromatographic analysis of
sugars. Inhibitors were directly added at their highest evaluated
concentration to assays containing no substrate. The control was
spiked with 2.5 μM glucose (G), fructose (F), and sucrose (S).
Table 1. Comparison of Methods for Glucose Detection
When Assessing the Inhibition of Human Maltase Activity by
EGCGa
SPE/hexokinase no SPE/HPAE-PAD
EGCG
(μM)
measured glucose
(mM) % CV
measured glucose
(mM) % CV
0 1.7 ± 0.2 8.6 2.7 ± 0.1 2.6
100 1.1 ± 0.0 2.4 2.1 ± 0.1 3.6
250 1.1 ± 0.1 7.0 1.8 ± 0.0 2.6
500 0.7 ± 0.1 17.4 1.3 ± 0.1 9.7
750 0.8 ± 0.1 13.7 1.4 ± 0.1 5.2
1000 0.7 ± 0.1 8.1 1.3 ± 0.0 3.3
mean 9.5 4.5
aGlucose was quantiﬁed relative to standard curves using HPAE-PAD
or by hexokinase-linked assay for samples that underwent SPE. Results
are presented as mean ± SD (n = 3). SD = standard deviation, %CV =
coeﬃcient of variation.
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required to achieve 50% inhibition. The IC50 values determined
from human and rat enzyme sources for green tea, EGCG, and
acarbose are summarized in Table 2. No inhibition was
observed for 5-caﬀeoylquinic acid at 200 μM on rat or human
maltase and sucrase activities. At a higher concentration of 500
μM, human sucrase activity was inhibited by 24 ± 6.1% but
with no signiﬁcant inhibition of human maltase.
4. DISCUSSION
In recent years, polyphenols have been investigated as potential
α-glucosidase inhibitors for the management and risk reduction
of type 2 diabetes, as an alternative to pharmaceutical
treatments such as acarbose. The methods used to date have
predominantly used enzyme preparations from rat intestine
rather than a human source.30−32 The homology between
human and rat sucrase−isomaltase is only 74%,33 and so it
cannot be assumed that inhibition of rat and human enzymes
will be equivalent. The active site sequence is conserved, but
there are diﬀerences in N-glycosylation, which can aﬀect
inhibition due to steric hindrance. The human sequence has 18
predicted N-glycosylation sites, while the rat has 16, only 9 of
which are in equivalent positions.33 Furthermore, some reports
even use a yeast α-glucosidase, which provides much less
relevant inhibition information. In congenital sucrase−
isomaltase deﬁciency (CSID) disorder, which occurs in 0.2%
Figure 7. Comparison of glucose detection methods for the inhibition
of maltase by EGCG. The amount of glucose produced was
determined using HPAE-PAD, or samples were passed through SPE
and then glucose determined using the hexokinase assay. The percent
inhibition was determined and presented as mean ± SEM (n = 3).
There was no signiﬁcant diﬀerence between the two detection
methods at any concentration.
Figure 8. Flowchart showing optimized enzyme assay conditions for determining sucrase and maltase inhibition using human Caco-2/TC7 cells as
the enzyme source. (A) Fully diﬀerentiated cells are lysed into assay buﬀer, and the speciﬁc activity of sucrase and maltase was determined in the
lysate using enzyme assays with a range of enzyme concentrations (40−320 μg total protein). The speciﬁc activity is then used to calculate the
amount of lysate to give 0.05 units of maltase activity or 0.02 units of sucrase activity. (B) Prewarmed cell lysate and the inhibitor are added to the
assay tube, and the reaction is started by the addition of 10 mM substrate (maltose or sucrose). Samples are incubated for 10 min at 37 °C, and
reaction terminated by denaturation at 95 °C for 10 min. Solid phase extraction is used to remove interfering inhibitors (indicated as optional
because it must be determined if the inhibitor interferes with the glucose product determination), and glucose is quantiﬁed using the hexokinase
assay.
Figure 9. Determination of inhibition of human sucrase and maltase.
Determination of IC50 values for sucrase and maltase inhibition by
acarbose (A and B), EGCG (C and D), and green tea (E and F).
Results are presented as mean ± SEM (n = 3).
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of people of European descent, genetic diﬀerences as small as a
point mutation can lead to lack of function.14 We therefore
conﬁrmed here that the sequence of sucrase−isomaltase in the
Caco-2/TC7 cell line is identical to human tissue sucrase−
isomaltase.
Another limitation of reports currently found in the literature
is that the assay parameters and details are not always presented
in full, which makes comparison of inhibition values among
diﬀerent reports impossible. Here, an inhibition assay was
optimized for sucrase and maltase using human Caco2/TC7
cell-free extracts as an enzyme source (Figure 8). The assay was
used to evaluate inhibition by some selected polyphenols and
polyphenol-rich extracts and data from the human enzyme
source were compared to those determined using a source of
rat intestinal enzyme.
The importance of optimizing the assay was demonstrated
because working kinetically outside of initial rates34 changed
the measured inhibition by acarbose. Substrate concentration,
although reported to be important when measuring inhib-
ition,35 was less critical. Papain proteolytically cleaves the
isomaltase stalk from the membrane,36 resulting in higher
speciﬁc activity for both sucrase and maltase. Because inhibition
of maltase by acarbose was the same whether the enzyme was
free or membrane-bound, this was not considered to be a
critical step to carry out for an optimized assay. When
considering methods for detecting glucose as the product, both
enzymatic (hexokinase) and chromatographic detection gave
equivalent IC50 values, but the latter gave a lower coeﬃcient of
variation. Critically, if the putative inhibitor interferes with the
glucose detection method, then solid phase extraction was
absolutely necessary before the step to determine glucose.
EGCG, green tea, and acarbose exhibited 1.4 to 4.8-fold
stronger inhibition of human sucrase compared to rat; for
maltase, the reverse was true (13.5 to 48-fold weaker). Sucrase
activity arises solely from the sucrase subunit of sucrase−
isomaltase, whereas maltase is derived from both the isomaltase
and sucrase subunits16 as well as other α-glucosidases such as
maltase glucoamylase (MGAM).16 In humans, SI provides the
majority of the maltase and of the isomaltase activities in the
intestinal brush border.33 MGAM is absent from Caco-2 cells,37
and it is a less-important enzyme for hydrolysis of sucrose and
maltase. Therefore, our method is speciﬁc for analyzing
inhibition of the brush border sucrase−isomaltase enzyme,
which also hydrolyses the majority of maltose in the intestine.
Our data suggest that the tested inhibitors are more eﬀective on
human compared to rat sucrase, and therefore, more substantial
eﬀects might be expected in humans compared to rats in vivo,
but there is not enough data in the literature to make this direct
in vivo comparison. This situation also applies in reverse for
maltase inhibition.
The IC50 of EGCG for rat sucrase has been reported to be
21832 and 169 μM,30 both stronger than we observed here
using rat enzyme; however, both used detection methods in
which EGCG interferes.38 The IC50 of EGCG for rat maltase
has been reported as 40 μM, somewhat weaker than that
observed here (14 μM). Reported results using the enzyme
from rat sources for acarbose, which does not interfere with
detection methods, were more comparable to ours (IC50 of 0.43
μM for maltase and 1.2 μM for sucrase).30 5-Caﬀeoylquinic
acid was reported to strongly inhibit maltase activity with Ki =
1.8 μM using a Drosophila expression system as the source of
mouse sucrase,39 but we did not observe inhibition of human
maltase even at 500 μM, and only weak inhibition of human
sucrase. Hence, 5-caﬀeoylquinic acid is not expected to have
any physiologically-relevant inhibiting eﬀects in humans, even
though it was previously reported to be a strong inhibitor.
Interference in the detection method, or the use of the mouse
sequence for the expression, could partially explain the dramatic
diﬀerence. Furthermore, glycosylation in the Drosophila
expression system diﬀers from mammalian: it lacks the ability
to produce complex N-glycans due to the absence of β-N-
acetylglucosaminidase.40
Use of the pharmacological strong inhibitor acarbose often
leads to gastrointestinal side eﬀects41 due to substantial
amounts of undigested starch and sugar reaching the colon.
Dietary compounds such as polyphenols exhibit weaker but
signiﬁcant inhibition when tested in volunteers in vivo,21 are
consumed every day, and show fewer side eﬀects. Other classes
of compounds may also demonstrate activity. For example, the
naturally occurring pentose sugar L-arabinose, which is a
speciﬁc sucrase inhibitor, did not cause gastrointestinal side
eﬀects in humans.19 Digestion of sucrose by sucrase can be rate-
limiting in the glycemic response in rats; in an oral sucrose
tolerance test with a formulation containing L-arabinose, the
incremental area under the curve for blood glucose was
signiﬁcantly reduced, while no change was observed in
comparable glucose or starch tests.42,43 In humans, pure L-
arabinose led to a delay in glucose absorption in response to
sucrose intake, and although there was no change in iAUC,
there were signiﬁcant positive changes in the hormones GLP-1,
GIP, and insulin.19
In summary, we report an optimized assay for estimating
inhibition of human sucrase and maltase activities derived from
the sucrase−isomaltase enzyme. When performing assays or
considering published inhibition data, any interference with the
glucose detection methodology must be considered, and
interfering compounds removed through SPE. Because this
introduces some variation, HPAE-PAD oﬀers an alternative
detection method which can improve accuracy because SPE is
not required. The current work highlights that the use of
human cells or rat tissues as the source of α-glucosidase
activities impacts the resulting inhibition and should be
carefully considered and reported to avoid reporting false
negatives or positives.
Table 2. Inhibition of Human and Rat Sucrase and Maltase Activitiesa
human rat
inhibitor sucrase IC50 maltase IC50 sucrase IC50 maltase IC50
acarbose (μM) 2.5 ± 0.5 5.7 ± 1.4 12.3 ± 0.6b 0.42 ± 0.02c
green tea (mg/mL) 1.0 ± 0.3 0.5 ± 0.003 1.8 ± 0.3d 0.035 ± 0.005b
EGCG (μM) 657 ± 150 677 ± 241 950 ± 86d 14 ± 2.0b
aResults are mean ± SD (n = 3). Acarbose was tested from 1 to 50 μM; green tea was tested from 0.5 to 5 mg/mL for sucrase and 0.05 to 1 mg/mL
for maltase, and EGCG was tested from 100 to 1500 μM for sucrase and 100 to 1000 μM for maltase. Independent sample t test was performed to
compare results between rat and human enzymes. bp < 0.001. cp < 0.01. dp < 0.05.
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